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Gain-of-Function Mutation of KIT Ligand
on Melanin Synthesis Causes Familial
Progressive Hyperpigmentation
Zhi-Qiang Wang,1,2,5 Lizhen Si,1,2,5 Quan Tang,1,2 Debao Lin,3,6 Zhangjie Fu,1,2 Jing Zhang,1,2
Bin Cui,1,2 Yufei Zhu,1,2 Xianghua Kong,4 Min Deng,1,2 Yu Xia,1,2 Heng Xu,1,2 Weidong Le,1,2
Landian Hu,1,2 and Xiangyin Kong1,2,*
Familial progressive hyperpigmentation (FPH) is an autosomal-dominantly inherited disorder characterized by hyperpigmented patches
in the skin, present in early infancy and increasing in size and number with age. The genetic basis for FPH remains unknown. In this
study, a six-generation Chinese family with FPH was subjected to a genome-wide scan for linkage analysis. Two-point linkage analysis
mapped the locus for FPH at chromosome 12q21.31-q23.1, with a maximum two-point LOD score of 4.35 (Ø ¼ 0.00) at D12S81. Haplo-
type analysis conﬁned the locus within an interval of 9.09 cM, ﬂanked by the markers D12S1667 and D12S2081. Mutation proﬁling of
positional candidate genes detected a heterozygous transversion (c. 107A/G) in exon 2 of the KIT ligand (KITLG) gene, predicted to
result in the substitution of a serine residue for an asparagine residue at codon 36 (p.N/S). This mutant ‘‘G’’ allele cosegregated perfectly
with affected, but not with unaffected, members of the FPH family. Function analysis of the soluble form of sKITLG revealed thatmutant
sKITLGN36S increased the content of the melanin by 109% compared with the wild-type sKITLG in human A375 melanoma cells.
Consistent with this result, the tyrosinase activity was signiﬁcantly increased by mutant sKITLGN36S compared to wild-type control.
To our knowledge, these data provided the ﬁrst genetic evidence that the FPH disease is caused by the KITLGN36S mutation, which
has a gain-of-function effect on the melanin synthesis and opens a new avenue for exploration of the genetic mechanism of FPH.Familial progressive hyperpigmentation (FPH [MIM
%145250]), also called ‘‘melanosis universalis hereditaria,’’
is a rare form of a congenital genetic disease causing hyper-
pigmentation. FPH was ﬁrst reported by Chernosky in
a two-generation family consisting of four individuals.1
The onset of the pigmentationwas either at birth or in early
infancy, and irregular patches increased with age in size,
number, and conﬂuence.2 This process was rapid during
childhood and slower during adolescence, and it resulted
in extensive hyperpigmentation of the conjunctive face,
neck, trunk, limbs, lips, oral mucosa, palms, and soles.3
FPHwas determined to be an autosomal-dominant inherit-
able disease, after Rebora’s report on an Italian family in
1989 and Lin’s report on a Han family from China in
1991.2,3 Theﬁrst locus for FPHwas reported at chromosome
19p13.1-pter, spanning 45.58 cM between D19S593 and
19pter in2006.4However, no candidate genehasbeen iden-
tiﬁed in this region, and the genetic basis and pathologic
mechanisms of FPH remain unknown. In an effort to
localize the gene for FPH, we undertook an entire genome
scan in the six-generation Chinese family with FPH re-
ported by Lin.3 We found signiﬁcant evidence for linkage
of the FPH-responsible gene to chromosome 12q21.31-
q23.1. Subsequently, a missense mutation in the KITLG
gene (OMIM *184785) was identiﬁed as being associated
with human FPH.We investigated a six-generation family, from a rural area
of Shandong Province of China, with typical features of
FPH. A complete family history was obtained, and 18
affected individuals (nine males and nine females) were
identiﬁed. Careful physical examination revealed that all
of the affected individuals in this family manifested
pigmentation disorders without the association of any
other system disease (Figure 1). For example, patient IV-1
(Figure 1A) is an affected 53-year-old male with hyperpig-
mentation on his hands, palms, limbs, conjunctive face,
neck, trunk, and soles. None of the affected members in
this family was found to have skin cancer. The pedigrees
with FPH showed an autosomal-dominant inheritance
pattern (Figure 1C).
This research has been approved by the ethical review
committees of the appropriate institutions. In total, 25
family members participated in this study, but only 17 are
informative for linkage analysis. Samples of peripheral blood
were obtained from all available family members after
informed consent was obtained, and genomic DNA was ex-
tractedwith theQIAmpDNABloodkit (QIAGEN,Germany).
A genome-wide screening was performed in this family
for determination of the chromosomal regions linked to
FPH, with the use of 382 ﬂuorescent microsatellite markers
covering 22 autosomes at a resolution of approximately
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Figure 1. Familial Progressive Hyperpigmentation in a Six-Generation Family
(A) The affected individual, IV-1, manifests a typical clinical feature of FPH. The hyperpigmentation can be observed on his hands (a),
palms (b), limbs (c), conjunctive face (d), neck (d), trunk (not shown), and soles (not shown).
(B)Histological appearance of the specimen.Normal skin froman age-gendermatched control (a) and hyperpigmented skin fromapatient (b) are
shown. Skin-biopsy specimens were stained with hematoxylin and eosin. Magnification: 310. In hyperpigmented skin, there is a significant
increaseof thenumber ofmelanocytes andof themelanin content in thebasal keratinocytes, aswell as a slight increase in the sizeofmelanocytes.
(C) Pedigree structure and haplotype of the family. Markers are listed from top to bottom: centromere-D12S83-D12S326-D12S1708-D12S1667-
D12S81-D12S351-D12S101-D12S2081-D12S346-D12S78-telomere. Black bars represent disease-carrying haplotypes. Question marks indicate
that the genotype is not determined. Squares indicate male family members; circles indicate female family members; blackened symbols indicate
affected members; open symbols indicate unaffected members.
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ampliﬁcation was performed in a total volume of 10 ml,
with the use of a PTC-225DNAEngine Tetrad (MJ Research,
USA) and standard conditions. PCR products were electro-
phoresed on a 5% standard denaturing polyacrylamide gel
with an Applied Biosystems 377XL DNA Sequencer. The
size of the allele was determined on the basis of an internal
size standard (GeneScan400HDROX,Perkin Elmer) in each
lane, and resultswere analyzedwithGeneScan3.0 andGen-
otyper 2.1 software (Perkin Elmer).
A two-point linkage analysis was conducted with the use
of the LINKAGE V5.10 software package,5 under an auto-
somal-dominant genetic model, with a disease-allele
frequency of 0.0001, evenly shared allele frequency, full
penetrance, and no sex difference. Pedigree drawing and
haplotype construction were carried out with the use of
the Cyrillic v2.0 software (Cyrillic Software, UK).
An initial genome-wide scan identiﬁed a locus for FPH at
chromosome 12q. The maximum two-point LOD score
obtainedwas 4.35withmarkerD12S81, at a recombination
frequency of Ø ¼ 0.00 (Table 1). The analysis of additional
markers (D12S83, D12S326, D12S1708, D12S1667,
D12S351,D12S101,D12S2081,D12S346,D12S78; Table 1)
further conﬁrmed the initial result. Conversely, no signiﬁ-
cant linkage with markers on other chromosomal regions
was found in this FPH family (Table S1, available online).
Pedigree and haplotype analyses were carried out, and
three recombinations were identiﬁed (Figure 1C). First, an
affectedmale individual (IV-1)hada recombinationbetween
D12S1667 and D12S81. Second, an affected female (V-12)
had a recombination between D12S1708 and D12S1667.
For the affected individual (V-3), recombination took place
betweenD12S101 andD12S2081. All of the combined infor-
mation indicates that FPH maps to the region of chromo-
some 12q21.31-q23.1 spanning approximately 9.09 cM
and ﬂanked by markers D12S1667 and D12S2081.
The above physical interval contained about 81 deﬁned
genes, and KITLG (GeneID: 4254) could be a plausible
candidate gene on the basis of chromosome position and
previous function analysis.6,7 Sequencing of the KITLG
gene was initially performed on genomic DNA derived
from patient V-5. Upon complete analysis of the coding
Table 1. Two-Point LOD Score Result between the Disease
Gene and Ten Markers of Chromosome 12q21.31-q23.1
Two-Point LOD Score at Ø
Marker 0.00 0.01 0.05 0.1 0.2 0.3 0.4
D12S83 –N –4.69 –2.05 –1.04 –0.26 0.02 0.07
D12S326 –3.95 –0.27 0.27 0.37 0.29 0.15 0.06
D12S1708 2.94 2.88 2.65 2.34 1.73 1.12 0.54
D12S1667 –0.63 2.76 3.10 2.93 2.29 1.51 0.72
D12S81 4.35 4.26 3.92 3.48 2.56 1.62 0.73
D12S351 2.94 2.88 2.62 2.30 1.64 1.0 0.44
D12S101 4.13 4.05 3.73 3.31 2.44 1.55 0.70
D12S2081 –N –0.52 0.07 0.24 0.28 0.21 0.11
D12S346 –N 0.55 1.09 1.17 1.03 0.74 0.38
D12S78 –N –0.24 0.42 0.63 0.68 0.54 0.30674 The American Journal of Human Genetics 84, 672–677, May 15and the adjacent intron regions of KITLG, a heterozygous
c.107A/G transversion in exon 2 of KITLGwas identiﬁed
in this patient but was not present in unaffected members
(Figures 2A and 2B). The transversion caused an aspara-
gine/serine exchange at amino acid 36 of the KITLG
protein sequence. This mutant ‘‘G’’ allele cosegregated
perfectly with family members affected with FPH, but not
with unaffected members. We conﬁrmed that c.107A/G
was not listed in the NCBI SNP database (dbSNP). Further-
more, we used sequencing to exclude it as a SNP in a panel
of 296 normal, unrelated, healthy Chinese individuals.
These results indicated that KITLG N36S was a mutation.
KITLG, also known as steel factor, stem cell factor, and
mast cell growth factor, binds to and activates KITand plays
a crucial role in the development and maintenance of the
melanocyte lineage in adult skin.7–11 KITLG exists in two
alternatively spliced transcripts, differing in exon 6. The
smaller splice variant of KITLG, lacking exon 6, encodes
a primarily membrane-bound form of KITLG (mKITLG).12
In contrast, the larger precursor contains exon 6, which co-
des for a membrane-proximal extracellularly located
protease-cleavage site. This site is readily cleaved by cell-
surface proteases for production of a soluble KITLG mole-
cule (sKITLG).13 The primary translation product of both
KITLG mRNAs contains a 25 aa signal sequence at the N
terminus, not found in the mature form of the proteins.8
Many studies have shown that the KIT and KITLG genes
play a critical role in the development of the melanocyte
and melanin synthesis in ﬁsh, salamanders, avians, and
mammals, although the expression pattern of KIT and
KITLG among different species is variable. In addition,
the dependence of melanocytes on KIT/KITLG signaling
for survival or proliferation shows species-speciﬁc differ-
ences.12,14–16 Previous studies revealed that many mutant
alleles of KITLG are lethal in homozygous mice and
produce a variable level of coat-color dilution in heterozy-
gous mice.17–19 In transgenic mice, speciﬁc targeting
expression of KITLG in the epidermis can rescue the loss
of melanocytes in the interadnexal epidermis, resulting
in a highly pigmented epidermis.6,20
KITLG is produced locally in human skin by epidermal
keratinocytes and endothelial cells.21–23 The signaling of
KITLG and its receptor KIT plays an important role inmela-
nocyte proliferation and pigment production.24–26 Injec-
tion of the soluble form of sKITLG into human skin, which
was explanted on nude mice, resulted in hyperpigmenta-
tion of the grafted skin tissue. On the contrary, injection
of theKIT- or KITLG-blocking antibodies into the explanted
human skin led to a loss ofmelanocytes.7 Similarly, patients
receiving KITLG treatment showed an increased number of
melanocytes and increasedmelanin at the site of the KITLG
injection, compared with noninjected tissue.27,28
Biopsies taken from the hyperpigmented areas of FPH
patients displayed strong hyperpigmentation of the epi-
dermia and increased melanin in the basal layer, but no
increase in the number of melanocytes within the
epidermis.2–4,29 To determine the effects of the p.N36S, 2009
Figure 2. Mutation Analysis of sKITLG
in a Family with FPH and Effects of the
Mutant sKITLG on Melanin Synthesis
(A) Sequence trace of the WT allele,
showing translation of asparagine residue
at codon 36 (AAT).
(B) Sequence trace of the mutant allele,
showing the heterozygous c. 107A/G,
which is predicted to result in the missense
substitution of serine (AGT) for asparagine
at codon 36 (p.N36S).
(C) The soluble form of sKITLGN36S signif-
icantly increases melanin content in A375
cells, compared with the WT sKITLG. A375
cells were incubated with 100 ng/ml WT
sKITLG and sKITLGN36S for 24 hr, respec-
tively. Cell pellets were dissolved in buffer
(1N NaOH, 10%DMSO) at 80C for 2 hr and
centrifuged for 10 min at 12,000 3 g.
Absorbance of melanin at 420 nm was
measured with TECAN Safire2 (USA). A
melanin standard curve was prepared with
the use of synthetic melanin (Sigma). Melanin content was normalized to the cell number. Significance was determined according to
a two-sided Student’s t test performed with Excel software. The results are shown as mean5 SD (n¼ 6), and similar results were obtained
when the experiments and measurements were repeated four times. Error bars indicate 5 SD.
(D) The soluble form of sKITLGN36S significantly increases the tyrosinase activity, compared with the WT sKITLG, in A375 cells. The A375
cells were treated as in melanin measurement for tyrosinase-activity analysis. The protein present in the supernatant was estimated by
the method of Lowry, with BSA used as the standard, then 40 ug of protein was incubated in1 ml sodium phosphate buffer (pH7.4, con-
taining 0.1% L-dopa) for 2 hr at 37C. The absorbance was monitored at 475 nm with TECAN Safire2 (USA). Significance was determined
according to a two-sided Student’s t test performed with Excel software. The results are shown as mean5 SD (n¼ 10), and similar results
were obtained when the experiments and measurements were repeated twice.substitution in KITLG on the melanin synthesis, we ex-
pressed the soluble form of wild-type (WT) sKITLG and
mutant sKITLGN36S in Escherica coli and puriﬁed the
expression products for further analysis (Figure S1). Coo-
massie brilliant blue staining revealed a single band for
each construct (WT and mutant) after SDS-PAGE, and
western blot analysis showed that both bands could be
recognized by human KITLG antibody (Figure S1).
The A375 human pigmented melanoma cells were
treated with WT and mutant sKITLGN36S, then melanin
content was measured. Our results indicate that the two
types of sKITLG can increase the melanin content of
each cell in treated A375 cells; melanin content increased
from 16.2 pg per cell (WT sKITLG) to 33.9 pg per cell
(mutant sKITLGN36S). Compared with the WT sKITLG,
the mutant sKITLGN36S signiﬁcantly increased the
melanin content, up to 209%. This indicated that the
mutant sKITLGN36S had a greater melanin-synthesis func-
tion than its WT form (Figure 2C). Many reports have
shown that tyrosinase is essential in melanin syn-
thase.30–34 We therefore measured levels of tyrosinase
activity in A375 cells treated with either WT sKITLG or
sKITLGN36S protein, according to Y.H. Huang et al.34
Consistent with the improved ability of the mutant
sKITLGN36S to induce melanin synthesis, the tyrosinase
activity increased signiﬁcantly in A375 cells after treat-
ment with mutant sKITLGN36S, compared to treatmentThe Amwith the WT sKITLG (Figure 2D). Together, all of these
results indicate that the mutant sKITLGN36S protein had
the ability to increase melanin synthesis. These results
are consistent with the biopsies of FPH patients who dis-
played increased melanin in the basal layer (Figure 1B).3
However, there was no proliferation difference found for
treated A375 cells between the WT and mutant sKITLG
(data not shown).
Although our experimental data show that the soluble
form of p.N36S mutant KITLG can increase the melanin
synthesis in A375 cells, we cannot exclude the role of the
membrane-bound formofmutantKITLG forhyperpigmen-
tation in FPH families. Indeed, reports have indicated that
mouse melanocytes require the membrane-bound form of
KITLG for survival.6 Additional work will be required for
determination of whether the membrane-bound form of
mutant KITLG plays a role in melanin synthesis.
Several human genetic diseases, such as dyschromatosis
universalis hereditaria (DUH [MIM %127500]), dyschro-
matosis symmetrica hereditaria (DSH [MIM #127400]),
and xeroderma pigmentation (XP [MIM #278700]), show
some overlap with FPH. DUH and DSH are pigmentary
dermatoses most commonly seen in Japanese and Korean
individuals. DUH is characterized by hyperpigmented
and hypopigmented ﬂecks and spots over much of the
body.35 DSH shows a characteristic mixture of hyperpig-
mented and hypopigmented macules of various sizes,erican Journal of Human Genetics 84, 672–677, May 15, 2009 675
limited largely to the dorsal aspects of the hands and feet.36
FPH can be differentiated from DSH and DUH on the basis
of the absence of hypopigmented lesions in patients. In
addition, the genes for DSH and DUH have previously
been mapped to chromosomes 1q21.3, 6q24.2-q25.2,
and 12q21-q23.35,37–39 Thus, the genetic basis of FPH is
likely to differ from that of DSH and DUH. With regard
to XP, it is an autosomal-recessive syndrome with clinical
manifestations of excessive freckling, depigmentation,
hyperpigmentation, skin aging, and a very high level of
early and multiple skin cancers.40 Although XP also resem-
bles FPH hyperpigmentation, FPH does not show the
atrophy, xerosis, or skin tumors usually observed in XP.
FPH is also likely to be a heterogenous disease, given that
C. Zhang et al. mapped the gene responsible for FPH to
chromosome 19p13.1-pter, spanning 45.58 cM between
D19S593 and 19pter, using genome screening on a three-
generation Chinese family. However, there was no gene re-
ported to be responsible for FPH in this family.4 In the
current work, we have mapped the dominant FPH gene to
the region at chromosome 12q21.31-q23.1. Candidate-
gene analysis revealed thatmutantKITLGN36Swas the crit-
ical gene for FPH in this family. Protein-function analysis
conﬁrmed that the soluble form of mutant sKITLGN36S
can increase the melanin content signiﬁcantly in A375
humanpigmentedmelanomacells, comparedwith theWT.
In conclusion, this report identiﬁed the p.N36S transver-
sion of KITLG responsible for inherited FPH. The data show
that the soluble mutant form, sKITLG, produces a gain-of-
function defect in melanin synthesis, possibly triggering
hyperpigmentation of skin in patients. These results will
provide important clues for understanding of themolecular
mechanismof pigmentation in FPHand increase our ability
to develop effective intervention strategies.
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